Pulmonx Execs Trim Holdings, Award New RSUs: A Confident Rebalancing Amid Deep Stock Decline

Insider Sales and a New RSU Grant: What Pulmonx Investors Should Note

Pulmonx’s Chief Science & Technology Officer, Radhakrishnan Srikanth, sold a combined 8,493 shares on March 2, 2026, mainly to cover tax obligations linked to vesting Restricted Stock Units (RSUs) that were granted in 2022‑2025. The sales were executed at $1.43 each, slightly below the $1.44 market price, and left Srikanth with 170,736 shares. The transaction coincides with a fresh RSU grant of 175,000 shares, effective March 2, 2026, which will vest quarterly over four years. This “sell‑to‑cover” pattern is typical for insiders with large RSU balances and signals no immediate liquidity pressure on the executive’s personal finances.

Broader Insider Activity Signals a Rebalancing Phase

While Srikanth’s activity is routine, the broader insider landscape shows a pronounced shift. CEO French Glendon E. III executed three large sales totaling 67,813 shares, and Chief Commercial Officer Rose Geoffrey Beran sold 7,031 shares across five trades. In contrast, both insiders recently increased holdings: Srikanth’s net shares fell to 170,736, but the new RSU grant pushes the potential future ownership to 345,736 shares. The pattern suggests insiders are pruning current positions while earmarking long‑term equity through RSUs, a move that can be interpreted as confidence in Pulmonx’s future prospects, despite the stock’s steep 80 % YTD decline.

Implications for Investors and Valuation

Pulmonx’s valuation remains distressed: a negative P/E of –1.08 and a 52‑week high of $8.12 contrasted with a low of $1.31. The recent insider activity—especially the CEO’s substantial sales—may heighten short‑term volatility, but the simultaneous RSU grant reflects a commitment to the company’s long‑term strategy. Investors should watch for the upcoming Q4 2025 earnings on March 4; if the company can demonstrate improving revenue or cost discipline, the insider RSU commitment may translate into a rally. Until then, the stock’s low liquidity and negative earnings suggest a cautious stance, with insiders’ actions serving as a useful gauge of their confidence rather than a definitive market signal.